Classic Chinese medicine ancient prescriptions are stared at by Japanese pharmaceutical companies, and domestic pharmaceutical companies have to lose another game?

On September 2nd, KRACIE Holdings, Japan, announced that its Kracie Pharmaceutical will build a new factory in China to create a new plant for Chinese medicine raw materials.

This is the second Japanese pharmaceutical company that recently announced in China to invest in Chinese medicine. Earlier, the largest Hanfang Pharmaceutical Enterprise Jincun in Japan, together with the cooperation party, plans to set up a joint venture with Wuhan Jianmin.

The most well -known in the country is children's biscuits food in China. But in fact, the company has a traditional Chinese medicine production enterprise in China: Qingdao Huazhong Pharmaceutical Co., Ltd. The second factory prepared by this time is located in Weihai, Shandong. It is planned to be put into use in the fall of 2023.

The new factory of the Japanese company KRACIE Pharmaceutical will be responsible for crushing Chinese medicine raw materials and producing Pueraria extracts. It plans to produce 400 tons of Gegen Decoction extracts per year. The final finished product will be manufactured by the factory in Takaoka City, Toyama Prefecture, Japan. KRACIE expects that the total production capacity of Pueraria raw materials will expand by 40%after the establishment of the Weihai plant.

Gegen Tang is an authentic Chinese ancient side. Now it is stared at by Japanese pharmaceutical companies to build factories in China to control the upstream raw materials. At the same time, many pharmaceutical companies in China are getting farther and farther from the goal of "keeping innovation" in Chinese medicine

Main products with Gegen Decoction

KRACIE Pharmaceutical is a company under Kracie Holdings and is known as Japan's largest over -the -counter Hanfang Pharmaceutical Production Enterprise.

The official website shows that there are nine major Hanfang medicines sold in it, including Angelica Paeonia San, Gegen Decoction, Bawei Dihuang Wan, Liu Shen Wan, etc. Among them, the cold medicine series developed with Pueraria as its core ingredients is the main product, including the Gegen Decoction extract EX tablets, the Gegen Decoction extract, and the Gegen Decoction oral liquid.

In fact, "Gegen Decoction" is the famous party in the "Treatment of Treatment of Febrile" in the "Treatment of Febrile Diseases" in the Chinese Eastern Han Medical Medicine, and is called "the first side of the watt and dispel evil". A large number of clinical studies have shown that Pueraous Decoction can effectively alleviate symptoms such as fever, headache, systemic soreness, thirst, etc., and shorten the course of disease. Modern pharmacological studies have confirmed that it has antiviral, anti -inflammatory, antibacterial, antipyretic, and regulating immunity.

Among Chinese pharmaceutical companies, only Ruiyang Pharmaceutical and Nanjing Xingyin Pharmaceutical have three batch Gegen Decoction products. Among them, the Gegen Decoction particles of Ruiyang Pharmaceutical are well -known. They are three types of new drugs and national traditional Chinese medicine protection varieties of Chinese medicine. They are included in the new crown pneumonia prevention and treatment catalog in Hubei, Shandong, Guizhou and other provinces. In August 2018, Gegen Decoction particles turned to OTC, and the growth rate of sales in the retail market was quite ideal.

However, in the domestic social software, with "Gegen Decoction" as a keyword, you can find that many young people can use the trend of the Chinese medicine Gegen Decoction in Japan. , "Japanese Royal Factory", there are also many fans of the Pueraous Soup of Kracie Pharmaceutical.

Traditional Chinese medicine is not as promoting, and it has become an Internet celebrity product in replacing Japanese companies to make "Hanfang Medicine". This phenomenon is actually many and thought -provoking.

When KRACIE Group jointly established Qingdao Huazhong Pharmaceutical in 1988, it was also called "Japan's Zhongyuan Textile Co., Ltd.". This is an old Japanese textile company, established in 1887. According to a report from Qingdao local media in 2006, when the Japanese army occupied Qingdao in 1938, the local gauze factory was rebuilt.

Today, KRACIE has continued to invest in the establishment of Chinese medicine companies in Shandong to capture the "rich mine" of Chinese medicine names.

Stones from other hills, can learn

With an outstanding production system and management technology, Japanese Chinese pharmaceutical companies such as Jincun have become the biggest competitors of China's international medicine internationalization.

In the international patent medicine market, the number of Japanese patent applications ranked first, and the export share accounted for nearly 80 %. For example, when Jincun, Japan has established more than 70 GAP medicinal materials planting bases in my country, local Chinese medicine companies have hindered the establishment of GAP time and effort, and it is difficult to manage. In the same period, Tongrentang's GAP base in the country does not exceed 10.

Domestic traditional Chinese medicinal materials are scattered, the production methods are primitive, and the price fluctuates greatly. In recent years, due to the repeated increase in the prices of Chinese medicine and raw materials, cost control is particularly difficult. At the same time, due to the lack of unified standards and testing methods in various links, the quality of the collected medicinal materials is different, etc., Chinese medicinal materials and Chinese patent medicine have always been the hardest hit area of ​​the "Flying Inspection" of the Pharmaceutical Bureau.

At the same time, the market conditions of Chinese medicine are not optimistic. In the past five years, the market sales of the same level of hospitals have been similar. The sales scale of domestic Chinese medicine retail market has been stagnant, and the growth is achieved by the increase in unit prices.

In such a market pattern, Ji Cai failed to let go of Chinese medicine. The provincial -level collection of provincial -level collections from Guangdong, Hunan, Shandong and other places is classified by commonly used Chinese medicines according to the general name. In order to avoid the fate of bargaining, branded Chinese medicine companies such as Tongrentang have withdrawn from the network and returned to the pharmacy channel sales.

In fact, there are many policies for Chinese medicine enjoyment. In March of this year, the "Fourteenth Five -Year Plan" Traditional Chinese Medicine Development Plan "was released, proposed to build a demonstration zone of a comprehensive reform of Chinese medicine and build a high -quality development highland for Chinese medicine and industry. Good.

Compared with Japanese Chinese medicine, in addition to the differences in modern production methods, local Chinese medicine companies have a long way to go in terms of brand building, market development, and image shape.

Is the transnational enterprise that has entered the hinterland, is it a catfish that lives dead water, or or the shark that swallows the local industry?The key is to depend on the determination of Chinese pharmaceutical companies.

Writing ｜ Li Ao

Edit ｜ Jiang Yun Jia Ting

Operation | Valley

Illustration ｜ Visual China

- END -